Weedie


Home / Newswire

v1.0.0
Home
Stocks
Warrants
Heatmap
Newswire
Shorts
Halts
Licenses

Weedstocks Newswire Feed

Weedstocks news RSS feed

Aphria plans for global cannabis leadership with international expansion acquiring leading assets in Latin America and the Caribbean

2018-07-17 08:00:30

Aphria medical brands to gain exposure to over 300 million people, roughly 9 times the size of Canada

LEAMINGTON, ON, July 17, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APH and US OTC: APHQF) is proud to announce the Company's planned expansion into Latin America and the Caribbean with the proposed acquisition of industry-leading companies in Colombia, Argentina, Jamaica and a right of first offer and refusal in respect of Brazil through a definitive share purchase agreement (the "Agreement") with Scythian Biosciences Inc. ("Scythian"). Aphria will acquire 100% of the issued and outstanding common shares of LATAM Holdings Inc. ("LATAM Holdings"), a direct, wholly-owned subsidiary of Scythian (collectively, the "Transaction").

Highlights of the Transaction include:

Colombia – Strategic Launch Pad into South America

...

Read more


REPEAT- Maricann License Approved by Maltese Government

2018-07-17 08:00:00

TORONTO, July 17, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce that Malta Enterprise (the country's official economic development agency and the government entity responsible for licenses) has approved Maricann's application to set up a business in Malta to manufacture finished dose medical cannabis.

This license allows Maricann to supply its Maltese operation with raw materials that will then undergo advanced post processing to create pure cannabis distillates, allowing for true pharmaceutical manufacturing. Commercial production of distillates is integral for the Company, as it advances the timeline for delivery of its full suite of products to those European markets where such products are legal.

“Maricann continues its path of organic growth and value acquisitions throughout the European Union, accessing key markets for differentiated products through Malta,” commented Ben Ward, CEO.  “We will continue to implement our template for success across Europe, as we expand from operations in Germany, Switzerland and Malta to new markets.  We’ve seen parabolic growth in new markets over the past two years, and will expect to continue to see new markets open.”

The Company has received an initial allocation of 2,750 square metres of industrial space.  The approval in Malta is conditional on a number of items including (i) operation of the business in compliance with applicable laws, (ii) compliance with certain reporting requirements, (iii) the Company's Malta subsidiary reaching an employment level of at least 28 full-time equivalent employees within three years from the start of operations, (iv) the Company's Malta subsidiary investing at least €9.5 million in improvements to the site, plant, machinery and equipment within three years from the allocation of the applicable site and (v) the Company obtaining a licence from the Medicines Authority.

About Maricann Group Inc.

...

Read more


Auxly Congratulates Streaming Partner CannTx Life Sciences on Obtaining Cultivation Licence

2018-07-17 07:00:00

VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) ("Auxly" or the "Company") is pleased to announce that Auxly’s streaming partner, CannTx Life Sciences Inc. (“CannTx”), has been granted a cultivation licence for its production facility in Puslinch, Ontario pursuant to the Access to Cannabis for Medical Purposes Regulations.

Chuck Rifici, Chairman and CEO of Auxly commented, "We want to congratulate the team at CannTx on obtaining their cultivation licence! This represents a major milestone and achievement for CannTx and for the broader Auxly business strategy. CannTx’s approach to cultivation, through a focus on micropropagation and LED enabled vertical farming, makes CannTx a unique project for the Auxly platform and we could not be more pleased to have them as a partner.”

DEAL TERMS WITH CANNTX

Pursuant to the definitive agreement entered on December 22, 2017, the Company has provided CannTx with $5,000,000 related to the initial costs for the phase I construction of CannTx's 30,000 square foot facility. In addition, the Company will provide CannTx with $7,000,000 related to the phase II expansion of the facility, subject to the Company completing satisfactory due diligence and the parties agreeing to a construction budget and timeline for the phase II expansion. The phase II expansion is expected to increase the cultivation area of the facility from approximately 10,000 square feet to effectively 24,000 square feet of pure cultivation space by using innovative vertical grow technology.

In consideration for the financing, the Company received a minority equity interest in CannTx and an entitlement to 33% of all cannabis (or cannabis-derived products including any cannabis trim) produced at the facility for a period of 10 years from the date of first sale at a fixed cost.

...

Read more


Maricann License Approved by Maltese Government

2018-07-17 00:15:00

TORONTO, July 17, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce that Malta Enterprise (the country's official economic development agency and the government entity responsible for licenses) has approved Maricann's application to set up a business in Malta to manufacture finished dose medical cannabis.

This license allows Maricann to supply its Maltese operation with raw materials that will then undergo advanced post processing to create pure cannabis distillates, allowing for true pharmaceutical manufacturing. Commercial production of distillates is integral for the Company, as it advances the timeline for delivery of its full suite of products to those European markets where such products are legal.

“Maricann continues its path of organic growth and value acquisitions throughout the European Union, accessing key markets for differentiated products through Malta,” commented Ben Ward, CEO.  “We will continue to implement our template for success across Europe, as we expand from operations in Germany, Switzerland and Malta to new markets.  We’ve seen parabolic growth in new markets over the past two years, and will expect to continue to see new markets open.”

The Company has received an initial allocation of 2,750 square metres of industrial space.  The approval in Malta is conditional on a number of items including (i) operation of the business in compliance with applicable laws, (ii) compliance with certain reporting requirements, (iii) the Company's Malta subsidiary reaching an employment level of at least 28 full-time equivalent employees within three years from the start of operations, (iv) the Company's Malta subsidiary investing at least €9.5 million in improvements to the site, plant, machinery and equipment within three years from the allocation of the applicable site and (v) the Company obtaining a licence from the Medicines Authority.

About Maricann Group Inc.

...

Read more


Tetra Bio-Pharma Targets Multi-Billion Dollar Fibromyalgia Market

2018-07-16 12:37:35

Co-development deal announced with Germany’s Storz & Bickel aims to improve delivery of cannabinoid-based pain relief

ORLEANS, Ontario, July 16, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced a co-development agreement with Storz & Bickel to use a specialized medical device known as the Mighty Medic, in combination with its PPP001 prescription drug as well as with additional indications and a future proprietary cannabinoid formulation. The Mighty Medic is a portable herbal vaporizer for cannabis use approved by Health Canada as a Class 11 medical device and as such, is eligible for reimbursement. The agreement allows Tetra to effectively bring PPP001 to patients suffering from fibromyalgia and other chronic pain conditions, significantly expanding the market potential for PPP001.

Fibromyalgia affects about 4 million U.S. adults or about 2% of the adult population1. The cardinal symptom associated with the condition is pain that can be deep, sharp, dull, throbbing, or aching, affecting the muscles, tendons, and ligaments around the joints throughout the entire body. Treatments aimed at pain relief are the primary treatment intervention including an increasing use of opioids. Among the most commonly prescribed medications used to treat fibromyalgia are Lyrica, Cymbalta, Xyrem and Vimpat.

PPP001 is a cannabinoid-based product that is currently being studied in a Phase 3 Health-Canada approved clinical trial for advanced cancer pain. Tetra will use a bridging strategy to leverage the clinical data that has been generated with the smokable formulation of PPP001, to expedite the marketing requirements in these indications and reduce the time needed to bring these products to market. The combination product of PPP001 with the Mighty Medic would signify an important economic benefit for patients.

According to Dr. Gordon D. Ko, MD, FCFP(EM), FRCPC, PhD, “fibromyalgia is difficult to treat and there is no one "magic bullet". As practitioners we have the daunting task of moving our patients from unrelenting neuropathic pain to improved function and a better quality of life,” said Dr. Ko. “The clinical use of medical cannabis in the management of fibromyalgia suggests these patients obtain significant relief. Moreover, the potential to reduce opioid use for these patients is a foremost consideration of using the Mighty Medic to deliver the cannabinoids and terpenes contained in PPP001 by inhalation.” Dr. Ko is Medical Director, Fibromyalgia clinics and Adjunct Lecturer at The Canadian Centre for Integrative Medicine, (Markham, Ontario) and Sunnybrook Health Sciences Centre, University of Toronto.

...

Read more


High Hampton Engages Leading Global Greenhouse Design Firm Aurora Larssen Projects Inc. for Design and Support of CoachellaGro Cannabis Cultivation Facility

2018-07-16 11:00:00

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./

TSX: ACB  CSE: HC

TORONTO and EDMONTON, July 16, 2018 /CNW/ - High Hampton Holdings Corp. (CSE: HC) ("High Hampton") and Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) are pleased to announce that High Hampton has engaged with globally leading hybrid greenhouse engineering and design consultancy Aurora Larssen Projects Inc. ("ALPS"), a wholly owned subsidiary of Aurora, for the design of its cannabis cultivation facility at CoachellaGro, near Palm Springs, California. With the recently awarded Conditional Use Permit (CUP) (see High Hampton press releases from May 3 and June 7, 2018), High Hampton now enters an active construction phase at CoachellaGro, and ALPS will advise the Company on aspects of design, engineering and the construction of its facilities.

Larssen Ltd ("Larssen"), now ALPS, was acquired by Aurora as a dedicated hybrid greenhouse design and consulting arm for its global operations. Led by renowned engineer Thomas Larssen, ALPS has set the industry standard in high-tech, automated, environmentally controlled cultivation facilities for over 30 years and excels in the successful implementation of cutting-edge automation features, and proprietary design characteristics that generate exceptional yields, as well as the use of advanced energy efficient materials and technologies. Larssen has been involved with over 1,000 projects around the globe, including Aurora Sky, a high-technology, 800,000 square feet, 100,000 kg per annum, low production cost hybrid facility, and is currently engaged with over 15 cannabis industry clients globally, including 5 Canadian licensed producers.

David E. Argudo, CEO/Director of High Hampton, commented, "As we near the start of construction in Coachella, we continue to assemble a best-in-class team for this next phase. By engaging and integrating the work of ALPS with Infrastructure Engineers Ltd and general contractor Vertical Construction Inc. we will be able to finetune our design plans ensuring the construction of highly-efficient cultivation facilities, resulting in high-quality, low-cost production. We are looking forward to working closely with ALPS and strongly believe that our operation will greatly benefit from their experience and technological advancements."

...

Read more


Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors

2018-07-16 09:00:00

VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the appointment of Julie M. Eastland to the Board of Directors, effective immediately. Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in public and private biotechnology companies. Most recently she was Chief Business Officer and Chief Financial Officer of Cascadian Therapeutics, where she negotiated and managed the $810M acquisition by Seattle Genetics in March 2018.

“We are extremely pleased to have Julie Eastland join our Board of Directors,” stated Dr. Patrick Gray, CEO of Pascal. “Ms. Eastland possesses the financial and corporate development experience that Pascal will need going forward. She has previously raised over $725M in both private and public offerings for Cascadian Therapeutics and other biotechnology companies. Ms. Eastland has strong relationships with investors, investment bankers and analysts covering the U.S. public biotech sector, and excellent experience in partnering, acquisitions, collaborations, and licensing. She will work closely with Pascal to align our scientific strategy with our financial goals.”

Ms. Eastland commented, “I believe Pascal’s portfolio of immuno-oncology therapeutic candidates holds great promise, and I look forward to working with Dr. Gray and the rest of the Board to support the advancement of these programs to create value for patients and shareholders.”

Ms. Eastland served as Chief Business and Financial Officer of Cascadian Therapeutics, formerly Oncothyreon Inc., (Nasdaq:CASC and ONTY) from September 2010 to March 2018. From 2006 to 2010, Ms. Eastland was the Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company. Prior to VLST, Ms. Eastland held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

The Company has also announced the retirement of Dr. Reinhard Gabathuler from the Pascal Board of Directors. “We are indebted to Dr. Gabathuler for his work with Pascal, previously known as Biommune,” Dr. Gray commented, “On behalf of our board of directors, I would like to thank Gaba for his leadership and direction of the company, and I wish him the very best in his future endeavors.”

...

Read more


WeedMD Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

2018-07-16 08:05:00

TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce the results of its annual meeting of shareholders and to provide a corporate update detailing its recently accomplished milestones and current growth initiatives.

“As a trusted and proven LP in the cannabis industry, WeedMD has a reputation for pursuing complimentary business and corporate development initiatives in the emerging cannabis market,” said Keith Merker, CEO of WeedMD. “We have a strong balance sheet which allows us to comfortably execute our expansion plans as well as provides us with the flexibility to continue pursuing strategic relationships and partnerships in Canada and internationally. We remain committed to our expanding medical business as well as capitalizing on the upcoming adult-use market opportunity.”

Go Forward Plan

WeedMD is focused on delivering shareholder value through disciplined execution of its core strategy: a differentiated medical platform, focused on long-term care and seniors market; product innovation, led by industry-leading genetics, a leading cultivation program, and research and development capabilities; and a multi-channel distribution strategy, with institutional supply agreements for both medical and adult-use markets. With more than $50 million in treasury, all of WeedMD’s operational and expansion commitments are fully funded.

Funded Capacity: WeedMD is fully funded for more than 640,000 sq. ft. of indoor and greenhouse production. The Company’s recently licensed state-of-the-art greenhouse, in Strathroy, Ontario is now operational, with two 10,000 sq. ft. grow rooms in cultivation and a further sixteen 10,000 sq. ft. flowering rooms coming online by year-end. Furthermore, the Company has begun retrofitting an additional seven acres of greenhouse onsite, expected to commence cultivation in early 2019. An additional 50 acres of land is also available on the property for low cost outdoor cultivation, pending regulations.

...

Read more


Namaste receives approval of Normal Course Issuer Bid to repurchase and cancel up to 25,308,136 shares and announces attendance at GritCAMP cannabis & crypto conference July 25th-27th

2018-07-16 08:00:30

VANCOUVER, July 16, 2018 /CNW/ - Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N) (FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that the Company has received approval from the TSX Venture Exchange (the "Exchange") for a Normal Course Issuer Bid ("NCIB") to repurchase for cancellation up to  25,308,136 common shares of its own capital through the facilities of the Exchange. The NCIB will be in place for a 12-month duration, commencing on July 18th, 2018 and ending July 17th, 2019. Additionally, Namaste is also pleased to announce that the Company will attend and present at Grit Capital Advisory's upcoming July 25-27th 2018 conference, GritCAMP.

Pursuant to the notice of intention filed with the Exchange, the Corporation intends to purchase for cancellation, through the facilities of the Exchange and at the market price of the Corporation's common shares ("Common Shares") at the time of purchase, up to 25,308,136 Common Shares, representing approximately 8.9% of the Company's issued and outstanding common shares and 10% of the Company's "public float" (as such term is defined in the TSX-V Corporation Finance Manual).

The NCIB will be conducted on behalf of the Company by Canaccord Genuity Inc. ("Cannacord"). The actual number of Common Shares that may be purchased and the timing of any such purchases will be determined by the Corporation and will be made in accordance with the requirements of the Exchange.

The Corporation will enter into a pre-defined plan with Cannacord to allow for the purchase of Common Shares by the Corporation at times when it ordinarily would not be active in the market due to internal trading blackout periods.

Namaste is pleased to announce that CEO Sean Dollinger will be presenting at GritCAMP's upcoming cannabis and crypto conference on July 25th-27th, 2018. Grit Capital Advisory firm is well-known for its aggressive "out of the box" thinking. The conference will feature 20 of the most exciting crypto, cannabis, gaming & health-tech companies in North America and will feature +50 international wealth managers, 1x1 company circuit, immersive games and competitions, unique skill building in personal cyber-security, presenting with flair, tricks of the trade tax planning, live pyrotechnics entertainment and much more.

...

Read more


Aurora Cannabis Selects Shopify to Power Global ECommerce Platform

2018-07-16 07:00:00

New ECommerce Platform to Benefit Both Medical and Adult-Consumer Use Customers

TSX: ACB

EDMONTON, July 16, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that it has reached an agreement with Shopify Inc. ("Shopify"), one of the world's leading multi-channel, online commerce companies, to leverage the Shopify platform as Aurora's ecommerce engine for medical and recreational cannabis distribution globally.

Working closely with Aurora Cannabis' industry-leading software engineering team, Shopify will assist in transitioning Aurora's current ecommerce site to a new, Shopify-developed platform, improving the customer experience for Aurora's current medical and future adult consumer use customers. One of the key benefits of the Shopify platform is its rapid and seamless scalability as Aurora executes on its domestic and international expansion strategy.

"Selecting Shopify allows Aurora to bring a world-class ecommerce solution to our patients and future adult consumer use customers," said Darryl Vleeming, CIO of Aurora Cannabis Inc. "Shopify's unique, industry leading platform provides a safe, secure and flexible ecommerce site that we can build on as we execute our global growth initiatives and enter new markets."

...

Read more